| Identification | Back Directory | [Name]
4-[[(3R,5S)-3,5-Dimethyl-1-piperidinyl]sulfonyl]-N-[5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]benzamide | [CAS]
2570797-85-0 | [Synonyms]
HSGN-94
4-[[(3R,5S)-3,5-Dimethyl-1-piperidinyl]sulfonyl]-N-[5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]benzamide | [Molecular Formula]
C23H23F3N4O4S | [MOL File]
2570797-85-0.mol | [Molecular Weight]
508.52 |
| Hazard Information | Back Directory | [Uses]
HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model[1]. | [in vivo]
HSGN-94 (2%; external use; twice daily for 5 days) decreases MRSA USA300 in infected wounds of mice and results resolution of inflammation in infection model[1].
| Animal Model: | MRSA murine wound infection model[1] | | Dosage: | 2% | | Administration: | External use; twice daily for 5 days | | Result: | Reduced the levels of the pro-inflammatory cytokines, monocyte chemo attractant protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), and interleukin-1 beta (IL-1β) in MRSA USA300 skin lesions. |
| [References]
[1] Naclerio GA, et al. Mechanistic Studies and In Vivo Efficacy of an Oxadiazole-Containing Antibiotic. J Med Chem. 2022 May 12;65(9):6612-6630. DOI:10.1021/acs.jmedchem.1c02034 |
|
|